Actinium Pharmaceuticals (NYSE:ATNM) Stock Price Down 4.3% – Here’s Why

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) shares traded down 4.3% on Thursday . The stock traded as low as $1.10 and last traded at $1.11. 288,753 shares were traded during mid-day trading, an increase of 89% from the average session volume of 152,679 shares. The stock had previously closed at $1.16.

Analysts Set New Price Targets

Separately, Stephens restated an “overweight” rating and issued a $5.00 price target on shares of Actinium Pharmaceuticals in a research report on Tuesday, March 31st. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $4.50.

Actinium Pharmaceuticals Price Performance

The firm has a market cap of $34.83 million, a P/E ratio of -0.80 and a beta of -0.06. The stock’s 50-day simple moving average is $1.19 and its two-hundred day simple moving average is $1.26.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Actinium Pharmaceuticals by 0.9% during the third quarter. Vanguard Group Inc. now owns 1,384,543 shares of the company’s stock valued at $2,215,000 after acquiring an additional 12,703 shares during the last quarter. Mayport LLC bought a new position in Actinium Pharmaceuticals during the third quarter valued at $35,000. AM Investment Strategies LLC purchased a new stake in shares of Actinium Pharmaceuticals during the fourth quarter valued at $40,000. Bank of America Corp DE boosted its stake in shares of Actinium Pharmaceuticals by 76.6% during the fourth quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock valued at $99,000 after purchasing an additional 34,176 shares during the period. Finally, AQR Capital Management LLC boosted its stake in shares of Actinium Pharmaceuticals by 278.6% during the first quarter. AQR Capital Management LLC now owns 63,249 shares of the company’s stock valued at $102,000 after purchasing an additional 46,545 shares during the period. Institutional investors own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.